Company ProfilePremium

Gujarat Alkalies and Chemicals Ltd.

Company Profile Analysis

Ticker: GUJALKALI.NS

ESOMAR 23 Corporate BadgeISO Certifications Badge
Gujarat Alkalies and Chemicals Ltd. - Company showcase

Year Founded & Workforce

1973

Gujarat Alkalies and Chemicals Ltd. logo

Gujarat Alkalies and Chemicals Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Gujarat Alkalies and Chemicals Ltd. Overview

GACL is a Government of Gujarat-promoted, multi-product chlor-alkali company and, on a consolidated basis with its 60%-owned subsidiary GACL-NALCO Alkalies & Chemicals Pvt Ltd (GNAL), the third-largest caustic soda producer in India with approximately 3,000 tonnes per day of capacity at Vadodara and Dahej (CARE, Aug 2026). Its strategic identity rests on integration: chlorine and hydrogen co-produced with caustic soda are captively converted into a basket of more than 36 products, from chloromethanes and hydrogen peroxide to phosphoric acid, poly aluminium chloride and chlorotoluene derivatives. The business remains structurally exposed to electrochemical-unit (ECU) price cycles and power costs, which account for roughly 30–34% of revenue. After two loss-making consolidated years (FY24, FY25), FY26 was near break-even, and Q1 FY27 delivered record revenue and margin expansion. The investment case turns on renewable-power substitution, value-added chlorine sinks, and the turnaround of GNAL.


What the company does

GACL makes caustic soda (sodium hydroxide) through brine electrolysis using membrane-cell technology. The process co-produces chlorine and hydrogen in fixed ratios. Caustic soda is sold as lye, flakes and prills to alumina, textiles, pulp and paper, soaps and detergents, rayon and chemical customers. Chlorine and hydrogen, which in India often have low or negative merchant value, are converted captively into derivatives: chloromethanes, hydrochloric acid, sodium hypochlorite, aluminium chloride, poly aluminium chloride, chlorinated paraffin, chlorotoluene derivatives (benzyl chloride, benzyl alcohol, benzaldehyde), and hydrogen peroxide. A separate potash line produces caustic potash and potassium carbonate. Phosphoric acid (including purified/food-grade) and hydrazine hydrate extend the portfolio into non-chlorine specialties.

Company's own description (FY26 Annual Report, paraphrased)

The company describes itself as a multi-product chemical manufacturer and one of India's leading producers of caustic soda lye, with vision language centred on being recognised as a dynamic, modern and eco-friendly chemical company with enduring ethics. Its mission statements emphasise responsible business conduct, continuous performance improvement through innovation, and the highest standards of ethics and product quality. Its letterhead tagline is "Promoting Green Technology".

Business and revenue model

Revenue model: ~100% product sales (manufactured chemicals). Minor service-like income arises from utility supply, infrastructure sharing and agency arrangements with GNAL (sale of chlorine, steam, power, DM water, nitrogen, etc.), and from hydrogen sold by pipeline (NOCIL contract from Feb 2026). No subscription or licensing income.

FY26 standalone composition: net external sales ₹4,246.50 Cr; other operating income ₹111.58 Cr; revenue from operations ₹4,358.07 Cr; other income ₹116.62 Cr (AR FY26).

Export share: exports of ~₹920 Cr in FY26 (~21% of revenue, derived) against imports of ~₹444 Cr, giving a natural FX hedge (CARE, Aug 2026).

Volume base: total production of all products 21,75,302 MT in FY26, up 3.03% from 21,11,229 MT (AR FY26).

Value-chain position

GACL sits in the upstream/intermediate tier of the inorganic chemicals chain. Inputs are salt (brine), electricity (its largest cost), natural gas, coal/biofuel for steam, potassium chloride, rock phosphate/phosphoric inputs and toluene. Outputs are commodity intermediates sold B2B. The company is integrated backward into power (90 MW gas-based captive plant, 171.45 MW wind, 36.42 MW solar, plus group-captive renewable SPVs) and forward into chlorine and hydrogen derivatives.

Customer types and end-markets

Per CARE (Aug 2026), products serve textiles, pulp and paper, alumina/aluminium, soaps and detergents, rayon, fertilisers, petroleum, pharmaceuticals, agrochemicals, water treatment, inks and paints. NALCO is a contracted offtaker of a prescribed quantity of GNAL caustic soda via tender-based work orders. The newly approved high-purity hydrogen peroxide plant targets semiconductor fabrication, solar-cell manufacturing and advanced electronics.

Independent characterisation

GACL is best understood as a cost-and-integration play on Indian chlor-alkali rather than a specialty chemicals company. Its earnings are dominated by the ECU spread (caustic + chlorine + hydrogen realisation minus power). The FY24–FY26 downturn exposed three structural pressures: a national capacity build-out (India 6.7 Mtpa by March 2026) outpacing demand, persistently negative chlorine realisations (₹7,000–8,000/MT in FY26), and heavy depreciation from a ₹2,000+ Cr capex wave (Dahej expansion, chlorotoluene, GNAL). Diversification is real but its contribution is not yet large enough to offset the caustic cycle.

Strategy

Stated strategic themes (FY26 AR, Q1 FY27 investor presentation, CARE PR — paraphrased)

  1. Green Chemistry / renewable power substitution: raise renewable share of electricity from ~35% to ~60% in the medium term through group-captive hybrid wind-solar SPVs, short-term renewable procurement (NVVNL, Tata Power, Kreate Energy, PR Energy) and own solar.

  2. Chlorine value maximisation: add captive chlorine sinks (two HCl synthesis units; chlorotoluene ramp-up; phosphoric acid using HCl) to escape negative merchant chlorine pricing.

  3. Value-added and high-purity products: high-purity/E-grade hydrogen peroxide for semiconductor and solar supply chains; food-grade phosphoric acid; expansion of caustic flakes and caustic potash.

  4. Cost leadership: membrane-cell efficiency, power-cost reduction (₹7.90/unit FY26 vs ₹8.42), replacement of steam generation with four biofuel/coal-fired boilers.

  5. Infrastructure sharing with GNAL to avoid duplication and lift utilisation at Dahej.

  6. Vision 2047: long-term strategy document approved by the Board on 23 Jul 2026 (content not publicly detailed in sources reviewed).

Initiative register (last 24 months)

DateInitiativeInvestmentStatus / intent
Nov–Dec 202462.7 MW hybrid RE with Aditya Birla Renewables (26% stake)Equity share not disclosedUnder execution by SPV
26 Mar 2025GIPCL 75 MW solar (group captive; 50% to GACL)₹45 Cr equityFully operative
16 May 2025HCl synthesis unit #1 (90–120 MTPD) at Dahej₹35 CrAbsorbs 80–100 TPD extra chlorine
Aug–Nov 202575.9 MW hybrid RE with CleanMax (26% stake)₹19.42 Cr (Nov 2025) + ₹32.33 Cr (Jun 2026)Under execution; June 2026 partnership referenced 75.9 MW wind + 84.34 MWp solar
2,025SPV with GMDC for 60 MW RE—Approved in principle
14 Feb 2026Hydrogen pipeline to NOCIL—~20,000 Nm3/day; ~₹9 Cr annual revenue; 5-year contract
6 Feb 2026Governance: ESG committee merged into CSR committee—Completed
29 May 20265,000 TPA high-purity H2O2 plant, Dahej₹67 Cr18 months from technology kick-off; ~₹42 Cr revenue potential; funded from internal accruals
23 Jul 2026HCl synthesis unit #2, Dahej₹55 CrIn-principle; HCl to feed phosphoric acid plant
23 Jul 2026Vision 2047 document—Approved
FY27–FY29Capex programme: food-grade phosphoric acid (Dahej), four biofuel/coal boilers, flakes & potash expansion, E-grade H2O2, maintenance₹1,300–1,400 Cr; 60–70% debt-funded (GSFS/financial institutions)Per CARE Aug 2026
FY24–FY28Capacity expansion + renewable programme (Q1 FY27 presentation references ~₹315 Cr across FY24–FY28 for selected projects; context partly unclear in excerpt)~₹315 CrNot fully verified

Medium-term financial targets / guidance

GACL does not publish formal numerical guidance. Implicit targets: renewable share ~60% (medium term); consolidated gearing ~0.40x maintained through capex (CARE expectation); CARE projects consolidated interest coverage improving above 4–5x and total debt/PBILDT below 3x in the near-to-medium term.

Sustainability commitments

Renewable-power scale-up (above); treated waste-water reuse via VJSPL (50 MLD STP, Vadodara); Q1 FY27-era commentary references a renewable share around 59% in some periods (ScanX) — this conflicts with CARE's ~35% FY26 figure; the difference likely reflects measurement basis (point-in-time vs annual, or a specific complex). Discrepancy flagged.

Products & Services

GACL states it has more than 36 products. Disclosed product-level capacity data is incomplete in the FY26 documents reviewed; capacities shown below are from company investor presentations where available and dated accordingly.

Chlor-alkali core

ProductDescription & key usesTarget customersCapacity / statusNotes
Caustic soda lyeNaOH solution (typically ~48–50%), membrane-cellAlumina, textiles, pulp & paper, soaps & detergents, chemicalsGroup ~3,000 TPD (lye + flakes, consolidated with GNAL) at 31 Mar 2026 (CARE). Standalone lye capacity cited as 5,85,750 MT at 31 Mar 2025 (IIFL summary)Flagship product; GACL third-largest producer in India
Caustic soda flakesSolid NaOH, for distant/export marketsExporters, detergent, textile, chemical buyersExpansion of flaking facilities part of FY27–FY29 capex (CARE)GNAL operates a flaking unit
Caustic soda prillsBead-form NaOHSpecialty/export——
Liquid chlorineCo-product, sold in tonners/tankers or pipedChemical, pharma, water treatment, PVC/EDC makers—Realisations negative (~₹7,000–8,000/MT) in FY26 (CARE)
Hydrochloric acidFrom chlorine + hydrogen synthesisSteel pickling, chemicals, captive phosphoric acidNew 90–120 MTPD unit (₹35 Cr, May 2025) plus second unit (₹55 Cr, Jul 2026) at DahejKey chlorine sink
Sodium hypochloriteBleach/disinfectantWater treatment, textiles, municipal——
Hydrogen (gas)Co-productNOCIL (pipeline, ~20,000 Nm3/day, ~₹9 Cr annual revenue, 5-year contract); captive H2O2Pipeline commissioned 14 Feb 2026Monetises surplus hydrogen

Chlorine derivatives

ProductDescription & usesTarget customersCapacity / status
Chloromethanes (methylene chloride, chloroform; carbon tetrachloride co-product)Solvents and refrigerant/fluorochemical feedstockPharma, agrochemicals, fluorochemicals, foamPlants at Vadodara and Dahej (Dahej plant adjacent to GNAL uses GNAL surplus power); capacity not disclosed in FY26 sources
Chlorotoluene derivatives: benzyl chloride, benzyl alcohol, benzaldehydeIntermediates for pharma, flavours & fragrances, plasticisers, agrochemicalsPharma, F&F, agro intermediates90 TPD project (~₹350 Cr) at Dahej; production started FY2024-25; ramp-up slower than expected (CARE 2026)
Aluminium chloride (anhydrous)Friedel-Crafts catalystDyes, pharma, agro intermediates—
Poly aluminium chloride (various grades)CoagulantMunicipal and industrial water treatment, paper—
Chlorinated paraffinPlasticiser / flame retardantPVC compounding, lubricants—
Sodium chlorateOxidantPulp bleaching (ClO2), chemicals—
Stable bleaching powder / other chlorine products†DisinfectionWater treatment—

Peroxide and hydrogen-based products

ProductDescription & usesTarget customersCapacity / status
Hydrogen peroxide (standard grades)Eco-friendly bleaching agentPaper & pulp, textiles, chemicalsCombined capacity 54,120 MTPA (100% basis) per June 2022 presentation (Vadodara 13,860; Dahej 40,260)
High-purity / electronic-grade hydrogen peroxideUltra-pure gradeSemiconductor fabs, solar-cell makers, electronics5,000 TPA (100%) plant approved 29 May 2026; ₹67 Cr; 18 months from technology kick-off; ~₹42 Cr annual sales potential. CARE also references an "E-grade" H2O2 facility in the FY27–FY29 capex plan
Hydrazine hydrateReducing agentAgrochemicals, pharma, blowing agents, water treatment10,000 TPA (80%) project approved FY2015-16; first lot dispatched FY2022-23†

Potash, phosphate and other inorganics

ProductDescription & usesTarget customersCapacity / status
Caustic potash lye & flakesKOHFertiliser (potassic), soaps, batteries, chemicalsInitial capacity 16,500 MTPA (historic presentation); expansion part of FY27–FY29 capex (CARE)
Potassium carbonate (granules, powder)Glass, detergents, foodGlass, chemicals—
Phosphoric acid (technical, purified/food-grade)Food, pharma, detergents, metal treatmentFMCG, food processors33,870 TPA food-grade project approved FY2015-16; new food-grade phosphoric acid plant at Dahej is a principal FY27–FY29 project (CARE)
Aluminium fluoride†Fluxing agentAluminium smeltersEarlier disclosures; not re-verified in FY26 sources

Pricing model

No product pricing disclosed. Caustic soda pricing is market-linked; GNAL–NALCO caustic sales are via competitive tenders; inter-company GACL–GNAL prices are based on production cost, demand, supply and market price (AR FY26 RPT annexure). CARE notes average caustic prices of US$452/MT in FY26 vs US$495/MT in FY25.

Financial Narrative

Basis of preparation

Published consolidated (equity method): GNAL accounted as JV; consolidated revenue equals standalone revenue. FY22–FY24 from Screener.in consolidated compilation; FY25–FY26 from AR FY26 Board's Report.

Rating-agency consolidated (full consolidation of GNAL): CARE's unaudited reconstruction (FY25–FY26 only).

  • "EBITDA (consolidated basis)" follows Screener's convention, which embeds the share of JV loss in operating expenses; FY26 derived as standalone EBITDA excluding other income (₹405.21 Cr) less share of JV loss (₹23.25 Cr). This reconciles exactly to reported FY26 consolidated PBT of ₹20.72 Cr.

Income statement (published consolidated, INR Cr)

Gross profit: not publicly disclosed in comparable form (Indian Ind AS P&L presents expenses by nature; aggregator data lumps raw material, power and other costs).

FY22 growth computed from Screener FY21 revenue of ₹2,429 Cr. Tax for FY22–FY24 derived from Screener tax rates. FY26 dividend is recommended/declared for FY26 (paid after 30 Sep 2026).

Margins (published consolidated, %)

Revenue CAGR FY22–FY26: 3.8% (derived). Screener reports a 5-year sales CAGR of ~8% (FY20/21 base).

Standalone vs. rating-agency consolidated (INR Cr)

Note: CARE's "published" standalone-equivalent TOI (₹4,055 Cr FY25; ₹4,329 Cr FY26) differs from AR revenue from operations because of CARE's classification conventions.

Quarterly trajectory (INR Cr)

Sources: Univest/Kotak Neo (Q1FY26), multibagg/company release (Q2 sales revenue ₹1,063 Cr — may be a net-sales figure), Kotak Neo (Q3 PAT), FilingReader/NSE (Q4), ScanX/CARE (Q1FY27). Q1 FY27: CARE reports TOI ₹1,245 Cr and PBILDT margin 17.81% (vs 10.55% in Q1 FY26); ScanX reports standalone revenue of ₹1,224.84 Cr and standalone PBT of ~₹110 Cr — discrepancy between sources on standalone revenue noted.

Balance sheet (published consolidated, INR Cr)

Notes:

  • FY22–FY25 from Screener consolidated balance sheet. FY26 equity is derived (FY25 equity ₹5,669 Cr + FY26 total comprehensive loss ₹362.65 Cr – dividend paid ₹116.03 Cr). FY26 full balance sheet not accessed.

  • Long-term borrowings at 31 Mar 2026: ₹367.64 Cr (company's "not a Large Corporate" disclosure, 24 Apr 2026). CARE published consolidated gearing of 0.11x at 31 Mar 2026 implies total debt of roughly ₹570 Cr (derived), and net debt of roughly ₹400 Cr.

  • Goodwill & intangibles: not material / not separately disclosed in sources reviewed.

  • Working capital: Screener working-capital days of 4 (FY22), 5 (FY23), -1 (FY24), -3 (FY25) — effectively zero/negative net working capital.

Cash flow (published consolidated, INR Cr)

Sources: Screener/Motilal Oswal (CFO, CFI, CFF, FCF); capex derived as CFO – FCF; dividends paid FY22–FY24 derived as prior-year DPS × shares; FY25–FY26 from AR FY26. FY26 cash flow statement not accessed.

Ratios

ROE/ROA derived on average equity/assets; ROCE and working-capital days from Screener; FY26 D/E from CARE (published consolidated); FY26 CCC is CARE's "operating cycle". CARE's own published-basis interest coverage: 7.78x (FY25), 7.95x (FY26). ROIC not separately computable from available data; ROCE used as proxy. Current ratio: not publicly disclosed in the sources reviewed.

Commentary on trends, inflections and drivers

FY22–FY23 (cycle peak). Revenue rose 55% in FY22 and another 20% in FY23 to a record ₹4,516 Cr as global caustic prices spiked in the post-COVID energy shock. EBITDA (excluding other income) approached ₹1,000 Cr in both years. However, FY23 already showed margin compression (26% to 21%) and a sharp step-up in depreciation (₹198 Cr to ₹276 Cr) as the Dahej expansion and new derivative plants capitalised (CWIP fell from ₹1,787 Cr to ₹544 Cr while net block jumped by ~₹1,550 Cr).

FY24 (collapse). Revenue fell 16% and EBITDA collapsed to ₹32 Cr (0.8% margin). Three effects compounded: (i) caustic soda prices normalised as domestic capacity additions created oversupply; (ii) chlorine realisations turned deeply negative; and (iii) the newly capitalised asset base carried depreciation of ₹377 Cr and interest of ₹45 Cr regardless of utilisation. Operating cash flow fell to ₹67 Cr, yet the company paid a record ₹173 Cr in dividends (FY23's ₹23.55/share), funded from the balance sheet.

FY25 (stabilisation). Revenue recovered 7% to ₹4,073 Cr and standalone EBITDA (incl. OI) reached ₹452.56 Cr, but GNAL's ₹135 Cr loss (₹80.94 Cr share to GACL) kept consolidated PAT negative (₹-65 Cr). OCI losses of ₹239 Cr (fair value of equity investments) eroded book value.

FY26 (near break-even). Revenue grew another 7% to ₹4,358 Cr; standalone EBITDA rose 15.3% to ₹521.83 Cr, helped by power-cost relief (₹7.90/unit vs ₹8.42/unit) and higher other income (+26.6%). GNAL's loss narrowed to ₹39 Cr, so consolidated PAT was ₹-2.41 Cr. CARE nonetheless judged the recovery well below its expectations (it had expected 13–15% standalone PBILDT margins vs 8.74% delivered), citing moderate caustic prices (US$452/MT), negative chlorine realisations, weaker downstream offtake and slow chlorotoluene ramp-up. A further ₹360 Cr OCI loss reduced equity again.

Q1 FY27 (inflection). Record revenue (₹1,245 Cr) and a 17.81% PBILDT margin on a sudden uptick in caustic prices; consolidated PAT of ₹54.98 Cr already exceeds the entire FY22–FY26 cumulative consolidated profit since FY24. GNAL also posted an 18.63% PBILDT margin. Sustainability is the key debate.

Balance-sheet quality. Leverage is low (D/E ~0.1x published; ~0.38x on CARE's full-consolidation basis including GNAL debt and CCD backstop). The more significant balance-sheet risk is not debt but the volatility of mark-to-market equity investments and contingent support obligations to GNAL.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

3,7594,5163,8074,072.914,358.07

Revenue growth YoY (%)

54.820.1-15.77.07.0

EBITDA excl other income, JV share embedded (INR Cr)

98494932279382

Other income (INR Cr)

46429092.14116.62

Depreciation & amortisation (INR Cr)

198276377392.30414.48

Operating income EBIT incl other income (INR Cr)

832715-255-2184

Finance cost (INR Cr)

6194550.5463.38

Profit before tax (INR Cr)

826695-300-71.2220.72

Tax expense (INR Cr)

266285-63-6.1023.13

Net profit (INR Cr)

560410-237-65.12-2.41

EPS basic (INR)

76.2255.78-32.25-8.87-0.33

EPS diluted (INR)

76.2255.78-32.25-8.87-0.33

Dividend per share (INR)

10.0023.5513.8515.8017.70

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA margin excl OI (%)

26.221.00.86.98.8

EBIT margin (%)

22.115.8-6.7-0.51.9

PBT margin (%)

22.015.4-7.9-1.70.5

Net margin (%)

14.99.1-6.2-1.6-0.1

Income Statement and Margin Analysis (%) (FY2025–FY2026)

MetricFY2025FY2026

Standalone revenue from operations (INR Cr)

4,072.914,358.07

Standalone EBITDA incl OI (INR Cr)

452.56521.83

Standalone EBITDA excl OI (INR Cr)

360.42405.21

Standalone EBITDA margin excl OI (%)

8.89.3

Standalone PAT (INR Cr)

15.8220.84

Standalone EPS (INR)

2.152.84

Standalone other comprehensive income (INR Cr)

-239.09-360.28

CARE full-consolidated TOI (INR Cr)

4,8495,091

CARE full-consolidated PBILDT (INR Cr)

451546

CARE full-consolidated PBILDT margin (%)

9.3110.72

CARE full-consolidated PAT (INR Cr)

-1112

CARE full-consolidated interest coverage (x)

2.423.56

CARE full-consolidated total debt to PBILDT (x)

4.803.74

CARE full-consolidated overall gearing (x)

0.370.38

Income Statement

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations, consolidated (INR Cr)

1,105.121,063—1,125.311,244.91

Consolidated PAT (INR Cr)

-13.7816.34-19.9514.9854.98

Standalone PAT (INR Cr)

7.79——7.9353.40

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

7,9778,3358,0237,987—

Net fixed assets (INR Cr)

2,7024,2504,6174,584—

Capital work in progress (INR Cr)

1,7875449579—

Investments (INR Cr)

2,1101,8312,0931,976—

Total equity (INR Cr)

5,8996,1396,0755,6695,190

Total borrowings (INR Cr)

594597544561—

Free cash & equivalents (INR Cr)

———138168

Net debt (INR Cr)

———423—

Other liabilities (INR Cr)

1,4841,5991,4041,756—

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash flow from operations (INR Cr)

73596067381—

Cash flow from investing (INR Cr)

-805-661-90-264—

Cash flow from financing (INR Cr)

12-140-277-145—

Capex derived (INR Cr)

908683231322—

Free cash flow (INR Cr)

-173277-16459—

Dividends paid (INR Cr)

5973173101.71116.03

Share buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE (%)

9.96.8-3.9-1.10.0

ROA (%)

7.45.0-2.9-0.8—

ROCE (%)

1311-40—

Debt to equity (x)

0.100.100.090.100.11

EBITDA interest coverage (x)

164500.75.56.0

Net debt to EBITDA (x)

———1.51.1

Asset turnover (x)

0.500.550.470.51—

Cash conversion cycle (days)

2915251926

Debtor days

29231724—

Inventory days

10111193110—

Payable days

10111986115—

Revenue by Region and Revenue by Region (%)

MetricFY2024FY2025FY2026

Total revenue from operations (INR Cr)

3,8074,072.914,358.07

Export revenue (INR Cr)

——920

Domestic revenue derived (INR Cr)

——3,438

Export share of revenue (%)

——21.1

Capital Markets

MeasureValueSource / date

Last verified price

₹640.30

NSE, 18 Sep 2026 (ex-dividend date)

52-week high / low

₹815.00 / ₹409.15

IIFL, Aug 2026

6-month return

+38.6%

Anand Rathi, to 18 Sep 2026

1-year return

+13.4%

Anand Rathi, to 18 Sep 2026

3-year price CAGR

~5%

Screener (as of ~Apr 2026; dated)

5-year price CAGR

~14%

Screener (as of ~Apr 2026; dated)

10-year price CAGR

~16%

Screener (as of ~Apr 2026; dated)

Valuation Snapshot

MultipleValueBasis

Market capitalisation

~₹4,702 Cr

7.344 Cr shares

TTM P/E (consolidated)

~71x

TTM PAT ₹66.35 Cr (Q2 FY26–Q1 FY27)

P/B

~0.91x (Screener-basis equity ~₹5,190 Cr) / ~1.15x (AR BVPS ₹556.82)

Two book-value conventions

EV

~₹5,100 Cr

Mkt cap + ~₹570 Cr debt – ₹168 Cr cash (derived)

EV/EBITDA FY26

~13.4x (consolidated basis ₹382 Cr) / ~9.8x (standalone incl. OI ₹522 Cr)

Derived

EV/Sales FY26

~1.17x

Derived

Dividend yield

~2.8%

₹17.70 / ₹640.30

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

10.0023.5513.8515.8017.70

Dividend payout on consolidated profit (%)

1342-43-178-5,400

Capital Instruments

InstrumentAmount (INR Cr)RatingHistory

Long-term bank facilities (term loan ₹242.63 Cr maturing 17 Mar 2028; cash credit ₹130 Cr)

372.63

CARE AA-; Stable (3 Aug 2026)

AA+ (Jun & Sep 2023) → AA (13 Feb 2024; reaffirmed Aug 2024, Aug 2025) → AA- (Aug 2026)

Short-term BG/LC

339.50

CARE A1+

Reaffirmed

Commercial paper

100.00

CARE A1+

Nil outstanding at 10 Jul 2026

Analyst Conclusions

Management guidance

No numerical guidance. Management messaging (AR FY26, Q1 FY27) emphasises cost reduction, renewable substitution and value-added products, and points to Q1 FY27 as evidence of improvement. CARE expects consolidated operating profitability and debt coverage to improve in FY27, but below its earlier expectations.

Consensus expectations

Not available (no consensus coverage identified).

Bull case

  1. Operating leverage is large: Q1 FY27 PBILDT margin of 17.81% vs 10.55% a year earlier turned a loss into ₹55 Cr quarterly PAT; with ~₹414 Cr of annual depreciation already absorbed, each percentage point of margin on ~₹4,800 Cr annualised revenue adds ~₹48 Cr EBITDA.

  2. Structural cost decline: power is ~30–34% of TOI; moving renewables from ~35% to ~60% via already-contracted SPVs could durably lower unit power cost below FY26's ₹7.90.

  3. Asset backing and yield: the stock trades near or below book (0.9–1.15x depending on convention), yields ~2.8%, carries low published leverage, and has a promoter group buying in the open market.

Bear case

  1. Cyclical peak risk: Q1 FY27 was driven by a sudden caustic-price uptick; with domestic capacity ~6.7 Mtpa and up to ~2 Mt more in the pipeline (Adani, Reliance), FY27 margins may revert to the 8–10% range of FY25–FY26.

  2. Chlorine remains a liability: negative realisations of ~₹7,000–8,000/MT persist and GACL lacks a PVC/EDC sink; derivative ramp-ups (chlorotoluene) have underdelivered.

  3. Capital allocation and credit drift: a ₹1,300–1,400 Cr, 60–70% debt-funded capex programme follows a capex wave that drove ROE to ~0%; CARE already downgraded to AA-, and GNAL support obligations and OCI volatility continue to erode book value.

Catalysts and monitorables (next 12 months)

  • Q2 FY27 results (expected early-to-mid November 2026): sustainability of the Q1 margin.

  • Caustic soda price trend (domestic and SE Asia CFR) and chlorine realisations.

  • GNAL quarterly profitability and any further GACL financial support.

  • Commissioning of HCl unit #1, progress on high-purity H2O2 kick-off, phosphoric acid plant award.

  • Start of power flow from Aditya Birla (62.7 MW) and CleanMax (75.9 MW) SPVs; reported power cost per unit.

  • Financing of the capex programme; CARE's next review (Aug 2027) and any outlook change.

  • Promoter group buying; any GoG restructuring of state chemical PSUs.

  • Publication of "Vision 2047" details.

Analyst verdict

GACL is a well-capitalised, state-sponsored chlor-alkali franchise that has spent three years paying for an investment wave which arrived just as the Indian caustic soda market tipped into oversupply. The numbers tell the story plainly: consolidated EBITDA fell from roughly ₹950–985 Cr in FY22–FY23 to ₹32 Cr in FY24, before recovering only to ~₹380 Cr by FY26, while depreciation doubled to ₹414 Cr. Return on equity has averaged around 1% for three years, and the rating agency has cut the company two notches since 2023.

Against that, the balance sheet is unusually robust for a cyclical, the promoter is accumulating shares, and management has chosen the right levers: cheaper power through renewable SPVs, captive chlorine sinks, and a modest, sensible push into high-purity chemicals. The first quarter of FY27 demonstrated how quickly earnings respond when ECU realisations firm, with GNAL also turning operationally profitable.

The core judgment is whether Q1 FY27 is a turn or a blip. Our assessment is that the cost-side improvements (power, hydrogen monetisation, HCl capacity) are structural and will lift through-cycle margins by a few points, but the revenue-side upswing is cyclical and exposed to new vinyl-integrated capacity from very large competitors. On that basis, GACL screens as a value-oriented, dividend-supported cyclical recovery rather than a compounder. At roughly book value and ~10–13x FY26 EV/EBITDA, the valuation already discounts a partial normalisation; upside requires FY27 consolidated EBITDA margins sustainably above 12% (the CARE downgrade threshold) and visible GNAL profitability. Investors should track quarterly chlorine realisations and power cost per unit more closely than headline revenue. Absent formal guidance and sell-side coverage, information asymmetry is high, and position sizing should reflect that.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleCategoryAppointed / tenureBackground (as disclosed)

Dr. Hasmukh Adhia, IAS (Retd.)

Chairman

Non-executive, nominee/non-independent

——

Smt. Avantika Singh (Aulakh), IAS

Managing Director

Executive (KMP)

MD since 3 Feb 2025

Also MD of Gujarat Gas, GSPC and GSPC LNG, JMD of Gujarat State Petronet; Chairperson of GNAL; previously Vice-Chairman & CEO, Gujarat Maritime Board; CEO, Gujarat Infrastructure Development Board

Dr. T. Natarajan, IAS

Director

Non-executive (GoG nominee)

Since 11 Sep 2024; retires by rotation, re-appointment at 2026 AGM

IAS 1996 batch; Additional Chief Secretary, Finance, Govt of Gujarat; ex-Senior Advisor to India's Executive Director at IMF; ex-Additional Secretary, Defence Production; BE (Guindy), MBA (Bharathidasan), Masters (Duke). Born 5 May 1971 (age 55)

Shri Bimal Julka, IAS (Retd.)

Independent Director

Independent

—

Retired IAS officer

Shri Nitin Shukla

Independent Director

Independent

Chair of Risk Management-cum-Safety Committee since 3 Feb 2024

—

Smt. Shridevi Shukla

Independent Director

Independent

——

Dr. Chinmay Ghoroi

Independent Director

Independent

—

Also a director of GNAL

Shri Sanjay Joshi

Independent Director

Independent

From 1 Jan 2026 (5-year term)

Global engineering leadership across India, Oman, Abu Dhabi, UK; ID at Ion Exchange (India); non-executive director at SLB Capturi India

Board of Directors — Smt. Avantika Singh, IAS

NameTitleSince

Smt. Avantika Singh, IAS

Managing Director

3 Feb 2025

Shri Shailesh Damani

Chief Financial Officer

8 Aug 2024

Shri Sanjay S. Bhatt

Company Secretary & Executive Director (Legal, CC & CSR)

KMP since 14 May 2014; nominee director on Aditya Birla Renewables SPV 4 since 5 Apr 2025

Shri G. S. Paliwal

Executive Director (Commercial); director on GNAL board

—

Shri Dineshkumar Hingrajia

GM (Energy); nominee director, Clean Max Sphere Energy

From 24 Nov 2025

Shri Pankaj Pujara

Advisor to MD

Relieved 31 Mar 2026

Board & Management Changes

DateChange

8 Aug 2024

Shailesh Damani appointed CFO

11 Sep 2024

Dr. T. Natarajan, IAS appointed director

3 Feb 2025

Avantika Singh, IAS appointed MD (succeeding Swaroop P., IAS)

16 May 2025

S. J. Haider, IAS appointed director (shareholders approved by postal ballot 5 Jul 2025)

31 Dec 2025

Rajiv Lochan Jain completes tenure as ID; S. J. Haider resigns

1 Jan 2026

Sanjay Joshi appointed Independent Director (approved by postal ballot 21 Mar 2026)

31 Mar 2026

Pankaj Pujara relieved as Advisor to MD

Major Shareholders

Holder categoryStake (latest)Source/date

Promoter & promoter group (GoG undertakings)

47.28%

CARE / exchange filings, 30 Jun 2026

— of which Gujarat State Investments Ltd

20.87%

CARE, Jun 2026

Foreign institutional investors

~3.3% (sources range 1.91%–3.30%)

Dhan/Share.market, Jun–Jul 2026

Domestic institutional investors

~1.6%–3.0% (sources conflict)

Share.market / Anand Rathi, Jun 2026

Public / retail and others

~46.4%

Share.market, Jul 2026

Competitive Landscape

Competitors by Segment

Business lineNamed competitorsNotes

Caustic soda / chlor-alkali

Grasim Industries (Aditya Birla Chemicals) — market leader; DCM Shriram (Jhagadia, Bharuch: India's largest single-site caustic facility at 2,225 TPD after an 850 TPD expansion); Tata Chemicals; Epigral (formerly Meghmani Finechem); Kutch Chemical Industries; TGV SRAAC; Chemplast Sanmar; Lords Chloro Alkali; Chemfab Alkalis (65,700 TPA); Nirma

GACL ranked third by capacity (CARE)

Prospective entrants

Adani (Mundra 2,200 TPD chlor-alkali plant under execution tied to 1 Mtpa PVC); Reliance (planned)

Nearly 2 Mt of new capacity potentially in pipeline (Price Watch, 2026)

Chloromethanes

SRF, Gujarat Fluorochemicals, Chemplast Sanmar

Captive fluorochemical integration advantages for peers

Hydrogen peroxide

National Peroxide; Aditya Birla group; imports (especially for electronic grade)

GACL historically among largest domestic producers

Phosphoric acid (purified/food)

Domestic fertiliser-linked producers and imports

—

Benzyl chloride/alcohol/benzaldehyde

Domestic specialty producers and Chinese imports

—

Peer Comparison FY2026

MetricGACLDCM Shriram (Chloro-Vinyl)

Revenue

₹4,358 Cr (standalone); ₹5,091 Cr incl. GNAL (CARE)

—

Revenue growth

+7.0%—

EBITDA margin

9.3% standalone excl OI; 10.7% CARE consolidated

—

Caustic capacity

~3,000 TPD (group)

Jhagadia 2,225 TPD (single site)

Company Snapshot

$503.2M

Revenue

1973

Founded

Gujarat, India

Headquarters

SWOT Analysis

Strengths

  • Scale: third-largest caustic producer with ~3,000 TPD group capacity (CARE, Aug 2026).
  • Integration: 36+ products allow captive chlorine and hydrogen use; e.g., hydrogen now sold by pipeline to NOCIL (~₹9 Cr/yr).
  • Low leverage: published consolidated D/E ~0.11x and CARE-full-consolidated gearing 0.38x at 31 Mar 2026.
  • Liquidity: free cash ₹168 Cr at FY26 end; CARE rates liquidity "strong"; short-term rating A1+.
  • Improving power economics: average power cost fell to ₹7.90/unit (FY26) from ₹8.42 (FY25); ~35% renewable share.
  • Shareholder returns despite losses: DPS of ₹13.85, ₹15.80 and ₹17.70 for FY24–FY26 while consolidated EPS was negative.
  • Natural FX hedge: exports ~₹920 Cr vs imports ~₹444 Cr (FY26).

Weaknesses

  • Profitability: consolidated net loss in FY24 (₹-237 Cr), FY25 (₹-65 Cr) and FY26 (₹-2.41 Cr); 3-year average ROE ~1% (Screener).
  • Margin shortfall: FY26 standalone PBILDT margin 8.74% vs CARE's 13–15% expectation.
  • Depreciation burden: ₹414 Cr in FY26, 2.1x FY22 level, from a capex wave not yet earning its cost of capital.
  • Chlorine economics: negative realisations ~₹7,000–8,000/MT.
  • GNAL drag: accumulated losses ₹633 Cr; ₹300 Cr CCD backstop.
  • OCI volatility: ₹239 Cr (FY25) and ₹360 Cr (FY26) OCI losses eroded book value.
  • CSR underspend in-year: ₹1.34 Cr spent vs ₹3.90 Cr obligation (balance moved to unspent account) — minor but notable.

Opportunities

  • Caustic upcycle: Q1 FY27 PBILDT margin of 17.81% shows operating leverage when prices rise.
  • Renewable target ~60% via 62.7 MW + 75.9 MW hybrid SPVs and GIPCL solar could cut the largest cost line further.
  • Electronics-grade chemicals: 5,000 TPA high-purity H2O2 (₹67 Cr capex; ~₹42 Cr revenue) tied to India's semiconductor and solar push.
  • Chlorine sinks: two HCl units (₹35 Cr + ₹55 Cr) and phosphoric acid plant.
  • GNAL turnaround: Q1 FY27 PBILDT margin 18.63% at GNAL; FY26 loss narrowed to ₹39 Cr from ₹135 Cr.
  • Chlorotoluene ramp-up: under-absorbed fixed costs today become operating leverage as utilisation rises.

Threats

  • Oversupply: national capacity ~6.7 Mtpa vs FY25 production 5.05 Mt.
  • New vinyl-integrated entrants (Adani Mundra 2,200 TPD; Reliance) could depress caustic prices.
  • Energy-price shocks: power cost ~30–34% of TOI.
  • Credit trajectory: CARE downgraded to AA- (Aug 2026), with a further negative trigger if consolidated PBILDT margin stays below 12% or debt/PBILDT exceeds 3.5x.
  • Regulatory/environmental: CARE flags tightening pollution norms or product bans as a downgrade trigger; chloromethanes (CTC) face Montreal Protocol constraints.
  • Capex execution: ₹1,300–1,400 Cr programme, 60–70% debt-funded, at a time of thin returns.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
5 Apr 2025S. S. Bhatt appointed nominee director on Aditya Birla Renewables SPV 4RE governance
15–16 May 2025Board appoints Talati & Talati as internal auditors; appoints S. J. Haider, IAS as directorGovernance
16 May 202590–120 MTPD HCl synthesis unit approved (₹35 Cr)Chlorine sink
May 2025FY25 results: standalone PAT ₹15.82 Cr; consolidated loss ₹65.12 Cr; ₹15.80 dividendSecond year of consolidated losses
Q1 FY26GNAL shutdown in Q1 FY26 (per CARE)Hit GNAL recovery
5 Jul 2025Shareholders approve S. J. Haider's appointmentGovernance
4 Aug 2025CARE reaffirms AA; StableRating
8 Aug 2025In-principle approval for 75.9 MW hybrid RE projectPower cost
14 Aug 2025Q1 FY26: revenue ₹1,105 Cr; consolidated loss ₹13.78 CrWeak start
26 Sep 202552nd AGM; Samdani Shah & Kabra appointed secretarial auditors to 2030Governance
30 Sep 2025Investment Committee approves CleanMax agreementsRE
18 Oct 202526% stake in Clean Max Sphere Energy acquiredRE
5 Nov 2025SHA and power-consumption agreements with CleanMax executedRE
6 Nov 2025Unclaimed FY2017-18 dividend (₹23.17 lakh) transferred to IEPFCompliance
7 Nov 2025Q2 FY26: sales ₹1,063 Cr (+10%), EBITDA ₹133 Cr (+7%), PBT ₹13 Cr; Talati & Talati re-appointed to 2028Improvement
14 Nov 2025₹19.42 Cr invested in CleanMax SPV rights issueRE
24 Nov 2025D. Hingrajia nominated to CleanMax SPV boardRE governance
31 Dec 2025R. L. Jain's ID tenure ends; S. J. Haider resignsBoard change
1 Jan 2026Sanjay Joshi joins as IDBoard strengthening
6 Feb 2026Q3 FY26: total income ₹1,075 Cr; consolidated loss ₹19.95 Cr; ESG committee merged into CSR committeeMixed
14 Feb 2026Hydrogen pipeline to NOCIL inauguratedNew revenue stream
Feb 202611th AMAI Alkali Industry Conference: India caustic capacity ~6.7 Mtpa by Mar 2026Industry oversupply context
20–27 Mar 2026GNFC (promoter) open-market purchases of GACL sharesPromoter confidence
21 Mar 2026Shareholders approve Sanjay JoshiGovernance
31 Mar 2026Pankaj Pujara relieved as Advisor to MDManagement change
24 Apr 2026Disclosure: not a "Large Corporate"; borrowings ₹367.64 CrDebt disclosure
29 May 2026FY26 results; ₹17.70 dividend; ₹67 Cr high-purity H2O2 plantNear break-even; value-added pivot
3 Jun 2026CleanMax partnership: 75.9 MW wind + 84.34 MWp solarPower cost; stock reacted positively
11 Jun 2026₹32.33 Cr further investment in CleanMax SPVRE
2 Jul 2026SEBI special window for transfer of physical shares (company publicises Feb 2026–Feb 2027 window)Investor services
22–23 Jul 2026Audit Committee/Board approve FY27 RPTs (₹1,000 Cr each GACL–GNAL and GNAL–NALCO)Related-party governance
23 Jul 2026Q1 FY27: record revenue; consolidated PAT ₹54.98 Cr; HCl unit #2 (₹55 Cr); Vision 2047Turnaround signal
27 Jul 2026Q1 FY27 investor presentation filedIR
3 Aug 2026CARE downgrades long-term rating to AA-; StableCredit negative
17 Jul 2026GNAL: Sugato Anando Basu appointed director (NALCO side); N. Ravi exits 30 Jun 2026JV governance
27 Aug 202653rd Annual Report filedDisclosure
3 Sep 2026GNAL AGMJV
18 Sep 2026Record date for ₹17.70 dividendShareholder return
25 Sep 202653rd AGM (VC)Governance

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 37,590 Mn in FY2022 to INR 43,580.7 Mn in FY2026.
Gujarat Alkalies and Chemicals Ltd. — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations37,59045,16038,07040,729.143,580.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. GACL 53rd Annual Report 2025-26 (NSE filing, 27 Aug 2026) (nsearchives.nseindia.com)
  2. CARE Ratings press release on GACL (3 Aug 2026) (careratings.com)
  3. CARE Ratings press release on GNAL (Sep 2025) (careratings.com)
  4. FY26 results newspaper publication (NSE, 30 May 2026) (nsearchives.nseindia.com)
  5. HCl unit #1 disclosure (NSE, 16 May 2025) (nsearchives.nseindia.com)
  6. Q1 FY27 investor presentation (NSE, 27 Jul 2026) (nsearchives.nseindia.com)
  7. GNAL 11th Annual Report and directors page · gnal.co.in
  8. Screener.in consolidated financials (screener.in)
  9. FilingReader (FY26 results) (filingreader.com)
  10. ScanX (Q1 FY27 results, HCl unit #2, Vision 2047) (scanx.trade)
  11. MoneyWorks4Me (H2O2 plant; NOCIL pipeline) · moneyworks4me.com
  12. DeshGujarat (HCl unit #2) (deshgujarat.com)
  13. Chemindigest (Sanjay Joshi appointment) (chemindigest.com)
  14. Gujarat Gas directorship disclosure (Avantika Singh Aulakh) (gujaratgas.com)
  15. Kotak Neo quarterly results (Q1, Q3, Q4) · kotakneo.com
  16. MarketsMojo annual results (marketsmojo.motilaloswal.com)
  17. Anand Rathi (price, shareholding, dividends) (anandrathi.com)
  18. Research360 corporate actions (dividend history) (research360.in)
  19. IIFL company summary (indiainfoline.com)
  20. Fibre2Fashion (H2O2 history, 2009) (fibre2fashion.com)
  21. Chemical Week (AMAI Conference, Feb 2026) (chemweek.mydigitalpublication.com)
  22. Price Watch (India caustic market, 2026) (price-watch.ai)
  23. Alchempro (India caustic production FY25) (alchempro.com)
  24. Chemical Weekly (AMAI data, Dec 2024) (chemicalweekly.com)
  25. Research & Markets (global caustic market, Jul 2026) (researchandmarkets.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.